Danaher Corporation $DHR Shares Purchased by Sierra Legacy Group

Sierra Legacy Group raised its stake in Danaher Corporation (NYSE:DHR) by 83.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,505 shares of the conglomerate’s stock after acquiring an additional 2,510 shares during the period. Sierra Legacy Group’s holdings in Danaher were worth $1,087,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Red Tortoise LLC boosted its position in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the period. Ramirez Asset Management Inc. purchased a new stake in Danaher in the second quarter valued at approximately $40,000. Costello Asset Management INC acquired a new stake in shares of Danaher in the first quarter valued at approximately $41,000. Strengthening Families & Communities LLC grew its position in shares of Danaher by 81.4% during the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after acquiring an additional 114 shares during the last quarter. Finally, Saudi Central Bank acquired a new position in shares of Danaher in the 1st quarter valued at $52,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $225.75 on Wednesday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The stock has a 50 day simple moving average of $206.70 and a 200-day simple moving average of $201.47. The company has a market cap of $159.46 billion, a price-to-earnings ratio of 46.55, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.71 earnings per share. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DHR. TD Cowen raised their price objective on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Barclays increased their price objective on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Bank of America dropped their target price on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Finally, Wall Street Zen cut Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 10th. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 29,728 shares of company stock worth $6,448,990 over the last 90 days. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.